Commodore Capital LP Q4 2020 Filing
Filed February 16, 2021
Portfolio Value
$183.9B
Holdings
28
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (28 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | CCCCC4 THERAPEUTICS INC | 481,094 | $15.9B | 8.67% | |
| 2 | TREURTRILLIUM THERAPEUTICS INC | 852,871 | $12.5B | 6.82% | |
| 3 | —CONSTELLATION PHARMCETICLS I | 423,708 | $12.2B | 6.63% | |
| 4 | —FIVE PRIME THERAPEUTICS INC | 532,000 | $9.0B | 4.92% | |
| 5 | KRON1USDKRONOS BIO INC | 298,839 | $8.9B | 4.85% | |
| 6 | OPHTEURIVERIC BIO INC | 1,274,261 | $8.8B | 4.79% | |
| 7 | ACRSACLARIS THERAPEUTICS INC | 1,336,275 | $8.6B | 4.70% | |
| 8 | COGTCOGENT BIOSCIENCES INC | 760,025 | $8.5B | 4.64% | |
| 9 | CBAYUSDCYMABAY THERAPEUTICS INC | 1,486,107 | $8.5B | 4.64% | |
| 10 | PMVPPMV PHARMACEUTICALS INC | 125,000 | $7.7B | 4.18% | |
| 11 | SNDXSYNDAX PHARMACEUTICALS INC | 330,315 | $7.3B | 3.99% | |
| 12 | XENEXENON PHARMACEUTICALS INC | 467,368 | $7.2B | 3.91% | |
| 13 | PTGXPROTAGONIST THERAPEUTICS INC | 347,500 | $7.0B | 3.81% | |
| 14 | MREOMEREO BIOPHARMA GROUP PLC | 1,854,278 | $6.6B | 3.61% | |
| 15 | TCE2CELLDEX THERAPEUTICS INC NEW | 356,431 | $6.2B | 3.40% | |
| 16 | VTGNUSDVISTAGEN THERAPEUTICS INC | 3,150,000 | $6.1B | 3.32% | |
| 17 | RLMDRELMADA THERAPEUTICS INC | 178,565 | $5.7B | 3.11% | |
| 18 | SPRYSILVERBACK THERAPEUTICS INC | 97,143 | $4.5B | 2.45% | |
| 19 | KURAKURA ONCOLOGY INC | 133,503 | $4.4B | 2.37% | |
| 20 | SURFUSDSURFACE ONCOLOGY INC | 467,796 | $4.3B | 2.35% | |
| 21 | GNCAQGENOCEA BIOSCIENCES INC | 1,765,901 | $4.3B | 2.32% | |
| 22 | —MERSANA THERAPEUTICS INC | 158,827 | $4.2B | 2.30% | |
| 23 | IMVTIMMUNOVANT INC | 83,782 | $3.9B | 2.10% | |
| 24 | IVAINVENTIVA SA | 231,000 | $3.4B | 1.82% | |
| 25 | —BCLS ACQUISITION CORP | 250,000 | $2.8B | 1.51% | |
| 26 | —CYCLACEL PHARMACEUTICALS INC | 264,690 | $2.1B | 1.12% | |
| 27 | —MILLENDO THERAPEUTICS INC | 925,000 | $2.0B | 1.08% | |
| 28 | —LIFESCI ACQUISITION II CORP | 100,000 | $1.1B | 0.58% |